Home / Market News / $FHTX
benzinga Corporate Catalyst Impact 85/100 ● negative

Foghorn Therapeutics shares are trading lower after the company and Lilly decided not to advance FHD-909 into the expansion phase and discontinued their SMARCA2 degrader collaboration.

Oct 1, 2026, 2:55 PM UTC · Primary ticker $FHTX

Foghorn Therapeutics shares are experiencing a significant decline due to the discontinuation of a key drug development program (FHD-909) and the termination of a collaboration with Eli Lilly. This news signals a major setback for Foghorn's pipeline and future revenue prospects, while Lilly's involvement was less central.

The discontinuation of FHD-909 and the SMARCA2 degrader collaboration with Lilly is a major negative catalyst for Foghorn Therapeutics. This drug candidate was a significant part of their pipeline, and its failure, coupled with the loss of a major pharmaceutical partner like Lilly, will severely impact their valuation and future growth prospects. Investors will likely re-evaluate Foghorn's entire pipeline and financial stability, leading to sustained downward pressure on the stock. For Eli Lilly, the impact is minimal as this was likely one of many early-stage collaborations, and its termination does not significantly alter their broader strategic outlook or financial performance. The biotechnology sector, particularly small-cap drug developers reliant on a few key programs, faces inherent risks from such clinical trial failures.

$FHTX negative Discontinuation of key drug program and collaboration
$LLY neutral Minor impact from collaboration termination
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.